Hemogenyx Pharmaceuticals (HEMO) RNS Announcements

Add to Alert list
Date Time Source Announcement
04 Mar 2022 11:05 AM
RNS
Second Price Monitoring Extn
04 Mar 2022 11:00 AM
RNS
Price Monitoring Extension
16 Feb 2022 07:00 AM
RNS
HEMO-CAR-T pre-IND Meeting Request
12 Jan 2022 07:00 AM
RNS
Hemogenyx Pharmaceuticals Partnership with Selexis
05 Jan 2022 07:00 AM
RNS
H.C. Wainwright Bioconnect Conference
22 Dec 2021 02:05 PM
RNS
Second Price Monitoring Extn
22 Dec 2021 02:00 PM
RNS
Price Monitoring Extension
22 Dec 2021 11:06 AM
RNS
Second Price Monitoring Extn
22 Dec 2021 11:01 AM
RNS
Price Monitoring Extension
20 Dec 2021 07:00 AM
RNS
Hemo-CAR-T partnership with WuXi ATU
13 Dec 2021 09:00 AM
RNS
Price Monitoring Extension
13 Dec 2021 08:55 AM
RNS
HEMO-CAR-T pre-IND Meeting Request
24 Nov 2021 02:38 PM
RNS
Convertible Loans Repayment
18 Oct 2021 07:00 AM
RNS
Lease of New York Mink Building Custom Laboratory
13 Oct 2021 08:30 AM
RNS
CDX Licence Agreement
12 Oct 2021 04:41 PM
RNS
Second Price Monitoring Extn
12 Oct 2021 04:36 PM
RNS
Price Monitoring Extension
30 Sep 2021 08:00 AM
RNS
Half-year Report
02 Sep 2021 07:00 AM
RNS
U.S. Approval of Monoclonal Antibody Patent
26 Jul 2021 07:00 AM
RNS
Appointment of Business Advisor & Board Observer
02 Jul 2021 11:23 AM
RNS
Corporate Presentation
25 Jun 2021 03:32 PM
RNS
Result of Annual General Meeting
16 Jun 2021 04:40 PM
RNS
Second Price Monitoring Extn
16 Jun 2021 04:35 PM
RNS
Price Monitoring Extension
15 Jun 2021 12:41 PM
RNS
Changes to 2021 AGM Arrangements
15 Jun 2021 11:06 AM
RNS
Second Price Monitoring Extn
15 Jun 2021 11:00 AM
RNS
Price Monitoring Extension
02 Jun 2021 04:11 PM
RNS
U.S. Approval and Issuance of CDX Antibody Patent
28 May 2021 02:00 PM
RNS
Posting of Annual Report & Notice of AGM
28 May 2021 08:52 AM
RNS
Total Voting Rights
27 May 2021 11:15 AM
RNS
Holding(s) in Company
27 May 2021 11:15 AM
RNS
Holding(s) in Company
26 May 2021 07:00 AM
RNS
Termination of Mint Facility; Admission of Shares
19 May 2021 07:00 AM
RNS
Director/PDMR Shareholding
18 May 2021 09:05 AM
RNS
Second Price Monitoring Extn
18 May 2021 09:00 AM
RNS
Price Monitoring Extension
18 May 2021 07:00 AM
RNS
Loan Notes Sale & Conversion; Facility Terminated
12 May 2021 12:00 PM
RNS
Publication of Supplementary Prospectus
12 May 2021 11:06 AM
RNS
Second Price Monitoring Extn
12 May 2021 11:00 AM
RNS
Price Monitoring Extension
05 May 2021 12:58 PM
RNS
Conversion of Convertible Loan Notes
30 Apr 2021 02:27 PM
RNS
Final Results
30 Apr 2021 07:00 AM
RNS
Total Voting Rights
26 Apr 2021 11:06 AM
RNS
Second Price Monitoring Extn
26 Apr 2021 11:00 AM
RNS
Price Monitoring Extension
26 Apr 2021 09:05 AM
RNS
Second Price Monitoring Extn
26 Apr 2021 09:00 AM
RNS
Price Monitoring Extension
26 Apr 2021 07:00 AM
RNS
Conversion of Convertible Loan Notes
16 Apr 2021 10:52 AM
RNS
Conversion of Convertible Loan Notes
14 Apr 2021 09:05 AM
RNS
Second Price Monitoring Extn

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

Hemogenyx Pharmaceuticals PLC is a preclinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases, like leukemia and lymphoma.

Hemo share price launched on LSE at 3p in 2017.

UK 100